IMMUNOTOPE is a clinical stage biotechnology company developing  immunotherapy products for the treatment and prevention of cancer and chronic viral infections.  Our products activate the patient’s own immune system to fight disease and prevent recurrence.  Our comprehensive approach to cancer therapy focuses on the critical, unmet need to diagnose cancer at the very earliest stages and to develop effective treatments that destroy tumors and prevent metastasis. Our product portfolio includes ovarian, breast, prostate, lung, pancreatic and colon cancer.   

Immunotope's platform provides the ideal combination of technologies for successful immunotherapy.  We are developing products and services that will: 

• Address the need for highly efficacious, curative treatments with minimal toxicity
• Use the exquisite sensitivity and specificity of the immune system for early detection of cancer
• Provide innovative tools and services for collaborative development of novel drug and diagnostic products
• Provide our shareholders with exceptional returns on their investment

We use proprietary immunoproteomics technologies to identify naturally processed and presented antigens associated with Major Histocompatibility Complex Class I and Class II molecules that are present only on diseased cells.

Immunotope has completed pre clinical characterization studies and preparing for phase I clinical study in lung and pancreatic cancer.